A small study involving Keytruda (pembrolizumab) showed that the cancer drug has been effective in shrinking or removing cancer tumors. With this, the U.S. Food and Drug Administration immediately approved the drug for patients with locally advanced or metastatic urothelial carcinoma.
The Keytruda is the first drug that has been approved for treating tumors that share a certain genetic profile, and thousands of patients are expected to benefit from it every year, according to The New York Times. Even without a control group, or a set of patients that did not receive the drug to compare with, the results are compelling and convincing.
The study, originally released in the Science journal, saw eighty-six patients participating in the trial. Sixty-six of them had tumors that shrank significantly. Among the 66 patients, 18 patients had their tumors disappeared.
Dr. Jack Jacoub, a medical oncologist at MemorialCare Cancer Institute, said that the results of the study, which was published in the journal Science last week, showed the effectiveness of targeting the immune system to treat cancer. This is in contrast to the common classification of cancers based on their location in the body. With pembrolizumab, the cancer cells are unmasked so that the immune system can identify and destroy them.
Keytruda is made by Merck & Co. and costs around $156,000 a year for patients with advanced lung, melanoma and bladder tumors. The study is ongoing, and the drug maker has also begun a trial to pair Keytruda with CTLA4 candidate MK-1308, per FiercePharma.
Merck hosted an encouraging analyst meeting at ASCO last week, and Morgan Stanley remains bullish on growth prospects of its new cancer drug. The Keytruda is the main catalyst for the company’s stock this year, which Zacks Investment Research rated “buy” in a research note published on May 26, according to a report from Smart Stock News.
Latest news on the cryptocurrency market
SEBA, a licensed and supervised Swiss bank providing a secure and easy-to-use bridge between digital and traditional assets, is looking...
Stocks rise as zombie companies proliferate
Stocks are hitting new highs but the foundation underneath is degrading fast. The insane behavior of markets can be blamed...
Agricultural stock news every investor needs to know
The market has been short in Corn as farmers have been holding. That means that there is very little Corn...
3 tech investment sectors to capitalize on the 5G revolution
It's been clear that the size of the expected revolution that 5G will create is certain to be huge. For...
4 important biotech conferences to attend this year
2020 is full of events, and here are some of the most interesting biotech conferences every professional should consider: Bio€quity...
- Crypto7 days ago
21 blockchain startups to compete at the European Blockchain Convention
- Business7 days ago
EssilorLuxottica is building an ambitious vision for 2020
- Africa7 days ago
Côte d’Ivoire and Ghana want to create a cocoa OPEC to support farmers
- Biotech7 days ago
German biotech companies continue to raise capital despite uncertainty